A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Inclusion Criteria: * Participants have given written informed consent approved by the ethical review board (ERB) governing the site * Female participants should be of non-childbearing potential * Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m\^2) * Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures * Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment) Exclusion Criteria: * Has had esophagus variceal bleeding within 3 months of check-in * Have the need to take medications that may interfere with how the liver removes the drug * Have evidence of cancer in the liver * Consumes excessively large amounts of drinks with caffeine or alcohol